Posted inBiotechnology
Scancell picks winner from phase 2 cancer vaccine face-off, choosing next-gen prospect for pivotal trial
Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, leading the British biotech to advance the next-generation cancer…